



Attn: Trading and Market Making/Legal and Compliance/Operations/Systems
UNIFORM PRACTICE ADVISORY (UPC #57-24) 08/22/2024 Acorda
Therapeutics Inc (ACORQ)

Notice has been received that the above Company's Modified First Amended Joint Chapter 11 Plan of Liquidation became effective on 8/21/2024. On the Effective date, all Existing Acorda Interests shall be extinguished, cancelled, and released and not entitled to Distribution or any recovery under the Plan. See the Company's Modified First Amended Joint Chapter 11 Plan of Liquidation.¹

Additionally, except to the extent that a holder of a Prepetition Notes Secured Claim agrees to less favorable treatment, in full and final satisfaction, settlement, and release of, and in exchange for a Prepetition Notes Secured Claim, on the Effective Date, or as soon thereafter as is reasonably practicable after each distribution date, the holders of outstanding Prepetition Notes Secured Claims will receive their Pro Rata share of (a) Net Cash Proceeds (to the extent of such remaining Net Cash Proceeds after the funding of clause (2) of the definition of Carve-Out Cash on the Effective Date in the amount of \$350,000) and (b) Liquidation Trust Beneficial Interests.

Issuer	Security Description	Maturity Date	CUSIP	Class
Acorda Therapeutics Inc.	Senior Secured Convertible Note	12/1/2024	00484MAC0	1

Members are reminded of their obligations under FINRA Rule 2111 if they continue to engage in transactions in the above security after the effective date.

Pursuant to FINRA Rule 11530, members are advised that, among other things, in contracts for securities where a public announcement or publication of general circulation discloses that the securities have been deemed worthless, deliveries shall consist a) the worthless securities or; or b) a Letter of Indemnity which shall grant the purchaser any rights and privileges which might accrue to the holders of the physical securities. Such deliveries shall operate to close-out the contract and shall be settled at the existing contract price pursuant to FINRA Rule 11530.

Questions regarding this notice should be directed to: FINRA Market Operations-1-866-776-0800.

¹ See e.g., In re: Acorda Therapeutics Inc., et al., Chapter 11 Case No. 24-22284 Company's Modified First Amended Joint Chapter 11 Plan of Liquidation of Acorda Therapeutics Inc and Its Affiliated Debtors.